联合临床与定量CT影像特征构建并外部验证用于评估胃癌微卫星不稳定状态的无创影像生物标志物及其预后价值
回顾性纳入396例胃癌患者治疗前CT图像,分为原始队列356例和外部验证队列40例,构建影像组学模型、临床模型及影像组学-临床联合模型判断微卫星不稳定状态。联合模型在各队列中鉴别能力最佳,训练队列AUC为0.836,外部验证队列为0.834,原始队列为0.750。联合模型未显示基于总生存期或无进展生存期的显著风险分层能力。
要点
- 联合临床与定量CT影像组学特征的模型鉴别胃癌微卫星不稳定状态的AUC在训练队列为0.836(95%CI 0.780-0.893)。
- 联合模型在外部验证队列AUC为0.834(95%CI 0.688-0.981),原始队列为0.750(95%CI 0.682-0.819)。
- 联合模型未显示基于总生存期或无进展生存期的显著风险分层能力(p > 0.05)。
核心结论
- 影像组学-临床联合模型可能作为评估胃癌微卫星不稳定状态的无创生物标志物,有助于临床决策,但其预后能力有限。
研究设计与样本
- 回顾性研究,从单中心和公共数据库招募396例胃癌患者,分为原始队列(n=356)和外部验证队列(n=40),使用治疗前CT图像。
诊断标准与关键数值
- 影像组学-临床联合模型基于临床特征和定量CT「Radscore」构建,用于判断微卫星不稳定状态。
- 联合模型在训练队列AUC为0.836(95%CI 0.780-0.893)。
- 联合模型在外部验证队列AUC为0.834(95%CI 0.688-0.981)。
- 联合模型在原始队列AUC为0.750(95%CI 0.682-0.819)。
临床应用与阅片要点
- 联合模型与任一独立模型相比显示更高临床净获益和显著阳性综合判别改善。
- 联合模型未显示基于总生存期或无进展生存期的显著风险分层能力(p > 0.05)。
局限性
- 联合模型未显示基于总生存期或无进展生存期的显著风险分层能力(p > 0.05)。
- 原文结论指出该联合模型提供的预后能力有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Molecular testing for microsatellite instability (MSI) status plays a vital role in the clinical management of gastric cancer (GC). Nevertheless, challenges of routinely applied technology for MSI determination exist. This study aimed to develop and validate a non-invasive imaging biomarker for MSI assessment in GC and explore its prognostic value.
METHODS: We retrospectively recruited 396 GC patients with pretreatment CT images from a single center and a public database and divided them into an original cohort (n = 356) and an external validation cohort (n = 40). The SMOTE algorithm was used to generate a balanced training cohort (n = 192) and the independent radiomics model, clinical model, and radiomics-clinic combined model were constructed for determining MSI status. The models' discrimination, calibration, clinical usefulness, and prognosis significance were evaluated by AUC, calibration, decision curve analyses, and Kaplan-Meier curve analysis, respectively.
RESULTS: The radiomics-clinic combined model derived from clinical and quantitative CT-based "Radscore" exhibited the best discriminatory abilities of MSI status in all cohorts, with AUCs of 0.836 (95% CI, 0.780-0.893) in the training cohort, 0.834 (95% CI, 0.688-0.981) in the external validation cohort, and 0.750 (95% CI, 0.682-0.819) in the original cohort, respectively. Meanwhile, the combined model demonstrated goodness of fitness, higher clinical net benefits, and significant positive integrated discrimination improvement compared with any independent model. While it showed no significant overall survival- or progression-free survival-based risk stratification ability (p > 0.05).
CONCLUSIONS: The radiomics-clinic combined model could be a potential non-invasive biomarker for MSI status in GC, which help clinical decision-making, nevertheless, provided limited prognostic ability.
引用
- Zhao, Gao, Bai, et al. Development and external validation of a non-invasive imaging biomarker to estimate the microsatellite instability status of gastric cancer and its prognostic value: The combination of clinical and quantitative CT-imaging features. Eur J Radiol. 2023. PMID: 36764010. doi:10.1016/j.ejrad.2023.110719
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。